Genentech, Xenon Enter Pain Partnership

Xenon Pharmaceuticals formed a strategic alliance worth up to $646 million with Genentech, a member of the Roche Group, to discover and develop compounds and companion diagnostics for the potential treatment of pain.
Genetic Engineering & Biotechnology News